<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130426</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT-iGlarLixi</org_study_id>
    <nct_id>NCT03130426</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi</brief_title>
  <acronym>REMIT-iGL</acronym>
  <official_title>Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether in patients with early type 2 diabetes, a&#xD;
      short-term intensive metabolic intervention comprising iGlarLixi, metformin, and lifestyle&#xD;
      approaches will be superior to standard diabetes therapy in achieving sustained diabetes&#xD;
      remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized controlled trial in 160 patients with&#xD;
      recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week&#xD;
      course of treatment with iGlarLixi, metformin and lifestyle therapy, and (b) standard&#xD;
      diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all&#xD;
      participants with HbA1C&lt;7.3% at the 12 week visit, glucose-lowering medications will be&#xD;
      discontinued and participants will be encouraged to continue with lifestyle modifications and&#xD;
      regular glucose monitoring. Participants with HbA1C â‰¥ 7.3% at this visit or who experience&#xD;
      hyperglycemia relapse after stopping drugs will receive standard glycemic management as&#xD;
      informed by the current Canadian Diabetes Association clinical practice guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The first occurrence of diabetes relapse</measure>
    <time_frame>64 weeks of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving drug-free diabetes remission</measure>
    <time_frame>24 weeks after randomization</time_frame>
    <description>Diabetes remission is defined as HbA1C &lt; 6.5% off diabetes drugs for at least 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving drug-free normoglycemia defined as HbA1C &lt; 6.0% off diabetes drugs for at least 12 weeks</measure>
    <time_frame>24 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of weight loss from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>(Weight at randomization - weight at 12 weeks)/(weight at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>(Waist circumference at 12 weeks - weight circumference at randomization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1C)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Expressed in Diabetes Control and Complications Trial (DCCT) units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iGlarLixi</intervention_name>
    <description>Dose is titrated to achieve fasting normoglycemia</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>glargine insulin / lixisenatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Dose is titrated to 2000 mg daily or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle therapy</intervention_name>
    <description>Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>diet and exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. men and women aged 30-80 years;&#xD;
&#xD;
          2. type 2 diabetes mellitus within 5 years of diagnosis;&#xD;
&#xD;
          3. stable diabetes drug regimen in the 10 weeks before randomization;&#xD;
&#xD;
          4. HbA1c 6.5-9.5% on no glucose lowering drugs, or &lt;/= 8.5% on 1 glucose-lowering drug,&#xD;
             or &lt;/= 8.0% on 2 glucose lowering drugs;&#xD;
&#xD;
          5. body mass index &gt;/= 23 kg/m2;&#xD;
&#xD;
          6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);&#xD;
&#xD;
          7. ability and willingness to self-inject iglarlixi; and&#xD;
&#xD;
          8. provision of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. current use of insulin therapy;&#xD;
&#xD;
          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;&#xD;
&#xD;
          3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR&lt;45&#xD;
             mL/min/1.73 m2 by MDRD formula;&#xD;
&#xD;
          4. history of lactic acidosis or diabetic ketoacidosis;&#xD;
&#xD;
          5. active liver disease or elevated alanine transferase (ALT) levels &gt;\= 2.5 times upper&#xD;
             limit of normal at the time of enrolment;&#xD;
&#xD;
          6. history or clinical suspicion of pancreatitis or medullary thyroid cancer, or a&#xD;
             calcitonin level &gt;/= 20 pg/ml;&#xD;
&#xD;
          7. cardiovascular disease (unless cleared for a moderate intensity exercise program by a&#xD;
             specialist) including: i. acute coronary syndrome, hospitalization for unstable&#xD;
             angina, myocardial infarction, or revascularization with coronary artery bypass&#xD;
             grafting or percutaneous coronary intervention; ii. peripheral vascular disease,&#xD;
             valvular heart disease, cardiomyopathy, aortic dissection, tachyarrhythmias,&#xD;
             bradyarrhythmias, prior stroke or TIA; iii. prior hospitalization for heart failure;&#xD;
             or iv. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves,&#xD;
             ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock, left&#xD;
             bundle branch block, second or third degree atrioventricular block).&#xD;
&#xD;
          8. history of any disease requiring frequent intermittent or continuous systemic&#xD;
             glucocorticoid treatment;&#xD;
&#xD;
          9. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;&#xD;
&#xD;
         10. history of any major illness with a life expectancy of &lt; 3 years;&#xD;
&#xD;
         11. history of injury or any other condition that significantly limits participant's&#xD;
             ability to achieve moderate levels of physical activity;&#xD;
&#xD;
         12. excessive alcohol intake, acute or chronic;&#xD;
&#xD;
         13. currently pregnant, or breastfeeding, or not using a reliable method of birth control&#xD;
             for the duration of the trial in all females with childbearing potential;&#xD;
&#xD;
         14. inability to take glargine, lixisenatide or metformin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia McInnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel Gerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joanne Liutkus</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>iGlarLixi</keyword>
  <keyword>Metformin</keyword>
  <keyword>Insulin</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

